Genetic Immunity, Inc. is a prominent therapeutic vaccine company dedicated to creating immune therapy solutions for various infectious diseases such as HIV, cancer, allergies, and viruses.
Their primary product candidate, Dermavir, is currently in Phase III clinical trials as an immune therapy treatment for HIV, showcasing the company's commitment to advancing innovative medical solutions.
Generated from their website's infomation